Vildagliptin elderly warnings removed

Vildagliptin was launched in 2008 as the first DPP4 inhibitor | SPL
Vildagliptin was launched in 2008 as the first DPP4 inhibitor | SPL

Prescribing information for vildagliptin (Galvus) and vildagliptin + metformin (Eucreas) no longer includes a cautionary statement about use in the elderly.

The warnings were removed after a pooled analysis of randomised, double-blind trials showed that the dipeptidyl peptidase 4 inhibitor is effective and well tolerated in patients aged 75 years or over with type 2 diabetes.

In this age group (n=25), vildagliptin, as add-on to metformin, was associated with a reduction in HbA1c of 1.1% from a baseline of 8.5% (p=0.0004), with 50% of patients (n=12) achieving an HbA1c of less than 7%. There were no reports of hypoglycaemic events or significant weight gain in elderly patients.

View Galvus drug record

View Eucreas drug record

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in